{"nctId":"NCT01239797","briefTitle":"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma","startDateStruct":{"date":"2011-06-20","type":"ACTUAL"},"conditions":["Lymphoma","Multiple Myeloma"],"count":646,"armGroups":[{"label":"Lenalidomide + Dexamethasone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lenalidomide","Drug: Dexamethasone"]},{"label":"Lenalidomide + Dexamethasone +Elotuzumab","type":"EXPERIMENTAL","interventionNames":["Drug: Lenalidomide","Drug: Dexamethasone (Oral)","Drug: Dexamethasone (IV)","Biological: Elotuzumab (BMS-901608; HuLuc63)"]}],"interventions":[{"name":"Lenalidomide","otherNames":["Revlimid®"]},{"name":"Dexamethasone","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"]},{"name":"Dexamethasone (Oral)","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"]},{"name":"Dexamethasone (IV)","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"]},{"name":"Elotuzumab (BMS-901608; HuLuc63)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.\n\nInclusion Criteria:\n\n* Documented progression from most recent line of therapy\n* 1-3 prior lines of therapy\n* Measurable disease\n* Life expectancy ≥3 months\n* Prior treatment with Lenalidomide permitted if:\n\n  1. Best response achieved was ≥Partial Response (PR)\n  2. Patient was not refractory\n  3. Patient did not discontinue due to a Grade ≥3 related adverse event\n  4. Subject did not receive more than 9 cycles of Lenalidomide and had at least 9 months between the last dose of Lenalidomide and progression\n\nExclusion Criteria:\n\n* Subjects with non-secretory or oligo-secretory or serum free light-chain only myeloma\n* Active plasma cell leukemia\n* Known Human immunodeficiency virus (HIV) infection or active hepatitis A, B, or C","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Median Progression Free Survival (PFS)","description":"Primary definition of Progression-free survival (PFS) defined as the time from randomization to the date of first documented tumor progression or death due to any cause. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (\\> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. The primary analysis of PFS was based on the primary definition using the Independent Review Committee (IRC) tumor assessment using the European Group for Blood and Bone Marrow Transplant (EBMT) criteria. Tumor assessments were made every 4 weeks (±1 week) relative to the first dose of study medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.35","spread":null},{"groupId":"OG001","value":"14.85","spread":null}]}]}]},{"type":"POST_HOC","title":"Median Progression Free Survival (PFS) - Extended Collection","description":"The time from randomization to the date of first documented tumor progression or death due to any cause. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (\\> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. Tumor assessments were made every 4 weeks (±1 week) relative to the first dose of study medication based on Independent Review Committee (IRC) tumor assessment using the European Group for Blood and Bone Marrow Transplant (EBMT) criteria.\n\nNote: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 06-Jul-2018)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.42","spread":null},{"groupId":"OG001","value":"14.92","spread":null}]}]}]},{"type":"PRIMARY","title":"Objective Response Rate (ORR)","description":"Objective response rate (ORR) defined as the percentage of participants with a best response on-study of partial response (PR) or better (stringent CR \\[sCR\\], complete response \\[CR\\], very good partial response \\[VGPR\\], and partial response \\[PR\\]) based on the Independent Review Committee (IRC) assessment of best response using the European Group for Blood and Bone Marrow Transplant (EBMT) assessment criteria. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (\\> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. Assessments were made every 4 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.5","spread":null},{"groupId":"OG001","value":"65.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Overall Survival (OS)","description":"Overall survival is defined as the time from randomization to the date of death from any cause. If a subject has not died, their survival time will be censored at the date of last contact (\"last known alive date\"). A subject will be censored at the date of randomization if they were randomized but had no follow-up. (Based on Kaplan Meier estimates)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.30","spread":null},{"groupId":"OG001","value":"39.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline of Mean Score Pain Severity (BPI-SF)","description":"The change from baseline of the mean score of pain severity at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 (\"No pain\", \"No interference\") to 10 (\"Pain as bad as you can imagine\", \"Highest imaginable interference\") numeric rating scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"2.237"},{"groupId":"OG001","value":"-0.04","spread":"2.408"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline of Mean Score Pain Interference (BPI-SF)","description":"The change from baseline of the mean score of pain interference at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 (\"No pain\", \"No interference\") to 10 (\"Pain as bad as you can imagine\", \"Highest imaginable interference\") numeric rating scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":"2.466"},{"groupId":"OG001","value":"0.48","spread":"2.868"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":238,"n":318},"commonTop":["Fatigue","Diarrhoea","Anaemia","Neutropenia","Constipation"]}}}